NASDAQ: EQ - Equillium, Inc.

Rentabilität für sechs Monate: -51.27%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Equillium, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Equillium, Inc.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis.

weitere details
It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2018-10-11
ISIN US29446K1060
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://equilliumbio.com
Цена ао 0.758
Preisänderung pro Tag: -16.93% (0.488)
Preisänderung pro Woche: -47.55% (0.773)
Preisänderung pro Monat: -47.01% (0.765)
Preisänderung über 3 Monate: -41.59% (0.694)
Preisänderung über sechs Monate: -51.27% (0.832)
Preisänderung pro Jahr: -82.45% (2.31)
Preisänderung über 3 Jahre: -87.68% (3.29)
Preisänderung über 5 Jahre: -92.05% (5.1)
Preisänderung seit Jahresbeginn: -45.22% (0.74)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0.6101 10
P/BV 0.9753 9
P/E 0 0
EV/EBITDA 0.0261 10
Gesamt: 6.13

Effizienz

Name Bedeutung Grad
ROA, % -26.39 0
ROE, % -59.08 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0572 10
Gesamt: 9.4

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 128.97 10
Rentabilität Ebitda, % -54.54 0
Rentabilität EPS, % -73.88 0
Gesamt: 2
Weitere Details

Institutionen Volumen Aktie, %
Decheng Capital Management III (Cayman), LLC 4447308 12.61
Decheng Capital LLC 4447308 12.61
Vanguard Group Inc 836930 2.37
Cota Capital Management, LLC 562278 1.59
Tang Capital Management, LLC 400000 1.13
JP Morgan Chase & Company 350031 0.99
Renaissance Technologies, LLC 347500 0.99
Geode Capital Management, LLC 172387 0.49
Commonwealth Equity Services, LLC 100000 0.28
Callan Capital LLC 99688 0.28

ETFAktie, %Rentabilität für das Jahr, %Dividenden, %
iShares Micro-Cap ETF 0.0032 17.09 1.54048
017.091.54



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Daniel Mark Bradbury Executive Chairman 158k 1961 (64 Jahr)
Mr. Bruce D. Steel C.F.A. Co-Founder, President, CEO & Director 779.87k 1966 (59 Jahre)
Ms. Christine Zedelmayer M.B.A., P.M.P. Senior VP & COO 553.73k 1970 (55 Jahre)
Dr. Stephen Connelly Ph.D. Chief Scientific Officer & Director 571.32k 1982 (43 Jahr)
Mr. Jason A. Keyes Chief Financial Officer N/A 1971 (54 Jahr)
Mr. Michael Moore Vice President of Investor Relations & Corporate Communications N/A
Dr. Matthew Ritter Ph.D. Senior Vice President of Corporate Development N/A
Mr. Joel M. Rothman Chief Development Officer N/A 1969 (56 Jahre)
Penny Tom Senior VP of Finance & Principal Accounting Officer N/A

Adresse: United States, La Jolla. CA, 2223 Avenida De La Playa - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://equilliumbio.com